

# CERTIFICATE

Survey of 28 October 2022

You have fulfilled the requirements of the External Quality Assessment with the following analysis

## Haemostasis 32 - Edoxaban (505):

Validity 12 months:

Edoxaban

(R) analysis is subject to the RiliBÄK

**Participant:**

2430

MUDr. Martin Spacek, PhD.

Vseobecna fakultni nemocnice v Praze

Centralni hematologicke laboratore ULBLD

U Nemocnice 2

12808 Praha 2

Düsseldorf, 14 December 2022



Prof. Dr. med. Michael Spannagl  
(Head of Reference Institution)



Prof. Dr. med. Dirk Peetz  
(Adviser)

# CERTIFICATE OF PARTICIPATION

Survey of 28 October 2022

You have participated in the External Quality Assessment with the following analysis

## Haemostasis 32 - Edoxaban (505):

Edoxaban

(R) analysis is subject to the RiliBÄK

**Participant:**

2430

MUDr. Martin Spacek, PhD.


Vseobecna fakultni nemocnice v Praze

Centralni hematologicke laboratore ULBLD

U Nemocnice 2

12808 Praha 2

Düsseldorf, 14 December 2022



Prof. Dr. med. Michael Spannagl  
(Head of Reference Institution)



Prof. Dr. med. Dirk Peetz  
(Adviser)